|Title||Serum lipoprotein lipase concentration and risk for future coronary artery disease: the EPIC-Norfolk prospective population study.|
|Publication Type||Journal Article|
|Year of Publication||2006|
|Authors||Rip, J, Nierman, MC, Wareham, NJ, Luben, R, Bingham, SA, Day, NE, van Miert, JNI, Hutten, BA, Kastelein, JJP, Kuivenhoven, JAlbert, Khaw, K-T, S Boekholdt, M|
|Journal||Arterioscler Thromb Vasc Biol|
|Date Published||2006 Mar|
|Keywords||Aged, Biological Markers, Case-Control Studies, Cholesterol, HDL, Coronary Artery Disease, Female, Follow-Up Studies, Humans, Lipoprotein Lipase, Male, Middle Aged, Predictive Value of Tests, Prospective Studies, Risk Factors, Triglycerides|
BACKGROUND: Lipoprotein lipase (LPL) is associated with coronary artery disease (CAD) risk, but prospective population data are lacking. This is mainly because of the need for cumbersome heparin injections, which are necessary for LPL measurements. Recent retrospective studies, however, indicate that LPL concentration can be reliably measured in serum that enabled evaluation of the prospective association between LPL and future CAD.
METHODS AND RESULTS: LPL concentration was determined in serum samples of men and women in the EPIC-Norfolk population cohort who developed fatal or nonfatal CAD during 7 years of follow-up. For each case (n=1006), 2 controls, matched for age, sex, and enrollment time, were identified. Serum LPL concentration was lower in cases compared with controls (median and interquartile range: 61 [43-85] versus 66 [46-92] ng/mL; P
CONCLUSIONS: Reduced levels of serum LPL are associated with an increased risk for future CAD. The data suggest that high LPL concentrations may be atheroprotective through decreasing TG levels and increasing HDL-C levels.
|Alternate Journal||Arterioscler. Thromb. Vasc. Biol.|
|Grant List||G0401527 / / Medical Research Council / United Kingdom |
MC_U106179471 / / Medical Research Council / United Kingdom
/ / Wellcome Trust / United Kingdom